55:22: So when we look again at their tumor growth

Quote:

---

55:22: So when we look again at their tumor growth through the spyre grams and through the waterfall plots, that we only had 6 patients here. But as you can see, all of them remain within the stable disease and many actually achieve partial responses over the course of the short study. And one of them actually had no measurable lesions on the PET scan at follow-up. And the remainder saw either stable disease or partial responses .

---

Quote:

---

"A new single agent CCR5 inhibitor, leronlimab, was started which coincided with a dramatic drop in MNs after 1 cycle of therapy. After 4 cycles of therapy, a scan confirmed a partial response of −39% in all target lesions . Additional blood draws found an increase in MNs at cycle 6 and 7, which was then associated with an 11% increase from the prior scan. Based on the lesion increase, the patient was started on FOLRIRI along with leronlimab, which saw a MN drop to 0 MN/CAML and the patient was found to have stable disease, with no changes in lesions observed ."

---